Mass spectrometer calibration of Cosmic Dust Analyzer

The time of flight mass spectrometer of the Cosmic Dust Analyzer (CDA) instrument aboard the Cassini spacecraft, is expected to be placed in orbit about Saturn to sample the ring material and satellite impact ejecta. Upon impact of an incident dust particle against the target plate at velocities of 5-100 km/s, some 10–8 to 10–5 times the particle mass of positive valence, single-charged ions is induced. These are analyzed via a time-of-flight mass spectrometer. Initial experiments employing a pulsed N2 laser (>300 µJ/pulse, 4ns, 337nm) acting on a suite of samples are described. The laser beam is focussed to deliver the light pulses onto a laser power density (1011 W/cm2) to simulate the impact of particles. Laser ionization produced a charge of 4.6 pC per pulse for aluminum alloy. Estimating that each Al+1 ion require energy of 5.98 eV ionization energy/ion implies that 10–5% of the laser energy produced ions and the present system has a 5% efficiency of collecting the laser-irradiation induced ions. Employing a multi-channel plate detector in this mass spectrometer yields for Al-Mg-Cu alloy and kamacite (Fe-Ni mineral) targets well defined peaks at 24 (Mg+1), 27 (Al+1) and 64 (Cu+1), and 56 (Fe+1), 58 (Ni+1) and 60 (Ni+1) dalton, respectively

Median Lethal Concentration and Efficacy of \u3ci\u3eBacillus Thuringiensis\u3c/i\u3e Against Banded Sunflower Moth (Lepidoptera: Tortricidae)

This study was conducted to determine dose-mortality response of the banded sunflower moth, Cochylis hospes Walsingham, to Bacillus thuringiensis Berliner and its effect on sunflower seed damage and yield. Of B. thuringiensis products tested, Cutlass AF and Javelin WG had the lowest LC50 values and highest slopes and relative potencies for C. hospes. Javelin WG was superior to the other B. thuringiensis materials tested and to Asana XL in preventing seed damage. Sunflower heads sprayed with Javelin WG had higher yields than sunflower heads sprayed with Asana XL or the other B. thuringiensis products tested. Asana XL is a standard chemical insecticide and is considered to give good control of banded sunflower moth. As an alternative to Asana XL, any of the B. thuringiensis products tested could be employed for control of C. hospes larvae and to reduce the impact on beneficials in sunflower fields

Median Lethal Concentration and Efficacy of \u3ci\u3eBacillus Thuringiensis\u3c/i\u3e Against Banded Sunflower Moth (Lepidoptera: Tortricidae)

This study was conducted to determine dose-mortality response of the banded sunflower moth, Cochylis hospes Walsingham, to Bacillus thuringiensis Berliner and its effect on sunflower seed damage and yield. Of B. thuringiensis products tested, Cutlass AF and Javelin WG had the lowest LC50 values and highest slopes and relative potencies for C. hospes. Javelin WG was superior to the other B. thuringiensis materials tested and to Asana XL in preventing seed damage. Sunflower heads sprayed with Javelin WG had higher yields than sunflower heads sprayed with Asana XL or the other B. thuringiensis products tested. Asana XL is a standard chemical insecticide and is considered to give good control of banded sunflower moth. As an alternative to Asana XL, any of the B. thuringiensis products tested could be employed for control of C. hospes larvae and to reduce the impact on beneficials in sunflower fields

Mass spectrometer calibration of Cosmic Dust Analyzer

The time-of-flight (TOF) mass spectrometer (MS) of the Cosmic Dust Analyzer (CDA) instrument aboard the Cassini spacecraft is expected to be placed in orbit about Saturn to sample submicrometer-diameter ring particles and impact ejecta from Saturn's satellites. The CDA measures a mass spectrum of each particle that impacts the chemical analyzer sector of the instrument. Particles impact a Rh target plate at velocities of 1-100 km/s and produce some 10^(−8) to 10^(−5) times the particle mass of positive valence, single-charged ions. These are analyzed via a TOF MS. Initial tests employed a pulsed N2 laser acting on samples of kamacite, pyrrhotite, serpentine, olivine, and Murchison meteorite induced bursts of ions which were detected with a microchannel plate and a charge sensitive amplifier (CSA). Pulses from the N_2 laser (10^(11) W/cm^2) are assumed to simulate particle impact. Using aluminum alloy as a test sample, each pulse produces a charge of ∼4.6 pC (mostly Al^(+1)), whereas irradiation of a stainless steel target produces a ∼2.8 pC (Fe^(+1)) charge. Thus the present system yields ∼10^(−5)% of the laser energy in resulting ions. A CSA signal indicates that at the position of the microchannel plate, the ion detector geometry is such that some 5% of the laser-induced ions are collected in the CDA geometry. Employing a multichannel plate detector in this MS yields for Al-Mg-Cu alloy and kamacite targets well-defined peaks at 24 (Mg^(+1)), 27(Al^(+1)), and 64 (Cu^(+1)) and 56 (Fe^(+1)), 58 (Ni^(+1)), and 60 (Ni^(+1)) dalton, respectively

Assessing the UK policies for broadband adoption

Broadband technology has been introduced to the business community and the public as a rapid way of exploiting the Internet. The benefits of its use (fast reliable connections, and always on) have been widely realised and broadband diffusion is one of the items at the top of the agenda for technology related polices of governments worldwide. In this paper an examination of the impact of the UK government’s polices upon broadband adoption is undertaken. Based on institutional theory a consideration of the manipulation of supply push and demand pull forces in the diffusion of broadband is offered. Using primary and secondary data sources, an analysis of the specific institutional actions related to IT diffusion as pursued by the UK government in the case of broadband is provided. Bringing the time dimension into consideration it is revealed that the UK government has shifted its attention from supply push-only strategies to more interventional ones where the demand pull forces are also mobilised. It is believed that this research will assist in the extraction of the “success factors” in government intervention that support the diffusion of technology with a view to render favourable results if applied to other national settings

The assessment of disability related to vision performance-based measure in diabetic retinopathy.

PURPOSE: To validate a third-generation performance-based measure of visual function titled Assessment of Disability Related to Vision (ADREV) in a study population of patients with diabetic retinopathy. DESIGN: Prospective, cross-sectional study. METHODS: Patients with nonproliferative or proliferative diabetic retinopathy, free from ocular comorbidity, were recruited from a single institute and completed the ADREV, the 25-Item National Eye Institute Visual Functioning Questionnaire (VFQ-25), and a clinical ophthalmic examination. Correlation, regression, and bootstrap analysis were conducted to determine the relationship between ADREV scoring and each of the study\u27s clinical and self-report measures of visual ability, while controlling for potential confounders. RESULTS: Ninety-one patients with diabetic retinopathy completed the study and analysis showed that the ADREV total and subscale scores shared a stronger relationship with the clinical measures of visual function than did the VFQ total and subscale scores. Regression analysis revealed that binocular visual acuity, contrast sensitivity, and better eye visual field were the best predictors of ADREV performance. CONCLUSIONS: The ADREV performance measure is a valid instrument for the assessment of disability related to vision in patients with diabetic retinopathy. Furthermore, the assessments provided by ADREV were more related to traditional clinical indicators of visual impairment than were the results of the self-report measure, specifically the VFQ-25

The emerging role of NG2 in pediatric diffuse intrinsic pontine glioma.

Diffuse intrinsic pontine gliomas (DIPGs) have a dismal prognosis and are poorly understood brain cancers. Receptor tyrosine kinases stabilized by neuron-glial antigen 2 (NG2) protein are known to induce gliomagenesis. Here, we investigated NG2 expression in a cohort of DIPG specimens (n= 50). We demonstrate NG2 expression in the majority of DIPG specimens tested and determine that tumors harboring histone 3.3 mutation express the highest NG2 levels. We further demonstrate that microRNA 129-2 (miR129-2) is downregulated and hypermethylated in human DIPGs, resulting in the increased expression of NG2. Treatment with 5-Azacytidine, a methyltransferase inhibitor, results in NG2 downregulation in DIPG primary tumor cells in vitro. NG2 expression is altered (symmetric segregation) in mitotic human DIPG and mouse tumor cells. These mitotic cells co-express oligodendrocyte (Olig2) and astrocyte (glial fibrillary acidic protein, GFAP) markers, indicating lack of terminal differentiation. NG2 knockdown retards cellular migration in vitro, while NG2 expressing neurospheres are highly tumorigenic in vivo, resulting in rapid growth of pontine tumors. NG2 expression is targetable in vivo using miR129-2 indicating a potential avenue for therapeutic interventions. This data implicates NG2 as a molecule of interest in DIPGs especially those with H3.3 mutation

A human MAP kinase interactome.

Mitogen-activated protein kinase (MAPK) pathways form the backbone of signal transduction in the mammalian cell. Here we applied a systematic experimental and computational approach to map 2,269 interactions between human MAPK-related proteins and other cellular machinery and to assemble these data into functional modules. Multiple lines of evidence including conservation with yeast supported a core network of 641 interactions. Using small interfering RNA knockdowns, we observed that approximately one-third of MAPK-interacting proteins modulated MAPK-mediated signaling. We uncovered the Na-H exchanger NHE1 as a potential MAPK scaffold, found links between HSP90 chaperones and MAPK pathways and identified MUC12 as the human analog to the yeast signaling mucin Msb2. This study makes available a large resource of MAPK interactions and clone libraries, and it illustrates a methodology for probing signaling networks based on functional refinement of experimentally derived protein-interaction maps

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.

BackgroundAdjuvant chemotherapy for resected early-stage non-small-cell lung cancer (NSCLC) provides a modest survival benefit. Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC. We aimed to evaluate the addition of bevacizumab to adjuvant chemotherapy in early-stage resected NSCLC.MethodsWe did an open-label, randomised, phase 3 trial of adult patients (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and who had completely resected stage IB (≥4 cm) to IIIA (defined by the American Joint Committee on Cancer 6th edition) NSCLC. We enrolled patients from across the US National Clinical Trials Network, including patients from the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) affiliates in Europe and from the Canadian Cancer Trials Group, within 6-12 weeks of surgery. The chemotherapy regimen for each patient was selected before randomisation and administered intravenously; it consisted of four 21-day cycles of cisplatin (75 mg/m2 on day 1 in all regimens) in combination with investigator's choice of vinorelbine (30 mg/m2 on days 1 and 8), docetaxel (75 mg/m2 on day 1), gemcitabine (1200 mg/m2 on days 1 and 8), or pemetrexed (500 mg/m2 on day 1). Patients in the bevacizumab group received bevacizumab 15 mg/kg intravenously every 21 days starting with cycle 1 of chemotherapy and continuing for 1 year. We randomly allocated patients (1:1) to group A (chemotherapy alone) or group B (chemotherapy plus bevacizumab), centrally, using permuted blocks sizes and stratified by chemotherapy regimen, stage of disease, histology, and sex. No one was masked to treatment assignment, except the Data Safety and Monitoring Committee. The primary endpoint was overall survival, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00324805.FindingsBetween June 1, 2007, and Sept 20, 2013, 1501 patients were enrolled and randomly assigned to the two treatment groups: 749 to group A (chemotherapy alone) and 752 to group B (chemotherapy plus bevacizumab). 383 (26%) of 1458 patients (with complete staging information) had stage IB, 636 (44%) had stage II, and 439 (30%) had stage IIIA disease (stage of disease data were missing for 43 patients). Squamous cell histology was reported for 422 (28%) of 1501 patients. All four cisplatin-based chemotherapy regimens were used: 377 (25%) patients received vinorelbine, 343 (23%) received docetaxel, 283 (19%) received gemcitabine, and 497 (33%) received pemetrexed. At a median follow-up of 50·3 months (IQR 32·9-68·0), the estimated median overall survival in group A has not been reached, and in group B was 85·8 months (95% CI 74·9 to not reached); hazard ratio (group B vs group A) 0·99 (95% CI 0·82-1·19; p=0·90). Grade 3-5 toxicities of note (all attributions) that were reported more frequently in group B (the bevacizumab group) than in group A (chemotherapy alone) were overall worst grade (ie, all grade 3-5 toxicities; 496 [67%] of 738 in group A vs 610 [83%] of 735 in group B), hypertension (60 [8%] vs 219 [30%]), and neutropenia (241 [33%] vs 275 [37%]). The number of deaths on treatment did not differ between the groups (15 deaths in group A vs 19 in group B). Of these deaths, three in group A and ten in group B were considered at least possibly related to treatment.InterpretationAddition of bevacizumab to adjuvant chemotherapy did not improve overall survival for patients with surgically resected early-stage NSCLC. Bevacizumab does not have a role in this setting and should not be considered as an adjuvant therapy for patients with resected early-stage NSCLC.FundingNational Cancer Institute of the National Institutes of Health